Research, Funding and Drug Development

Improvements in outcomes for cancer patients require continued research and innovation.  ACS CAN advocates for robust federal funding for cancer research, as well as research and drug approval policies that accelerate the development of new treatments while still ensuring patient safety.

Research, Funding and Drug Development Resources:

Clinical trials are pivotal to advancements in cancer treatment, but patient enrollment in these trials remains a challenge. Clinical trial matching services facilitate patient enrollment in clinical trials by identifying potential trials for interested patients and their proxies (e.g., caregivers and providers), and in some cases by providing other support services such as educational materials or personnel who can answer questions or assist patients.

Leading health care companies and organizations representing patients, providers, laboratories and diagnostic manufacturers called on Senate and House leaders to advance legislation that would reform and modernize the process for bringing innovative diagnostics and clinical laboratory tests to ma

The objective of cancer research is to generate new knowledge that can be used to improve survival and quality of life for patients with cancer. Clinical trials are the key step in advancing potential new cancer treatments from the research setting to the cancer care clinic, and patient participation in trials is crucial to this success.

The American Cancer Society Cancer Action Network joined 77 other organizations in a letter to leadership in the U.S.

ACS CAN supports the coverage of FDA-approved NGS panels, and also supports the coverage of panels used as part of NCI clinical trials.  CMS is encouraged to reconsider limitations on patient eligibility and is urged to create clear and achievable requirments for evidence development. 

Twenty two organizations joined to express concern with pending righ-to-try legislation under consideration in the House of Representatives.  

The costs of conducting cancer research include a variety of specific items ranging from researcher salaries, to laboratory supplies, along with utilities and maintenance.  

ACS CAN along with over 80 other patient organizations provided support and feedback to FDA regarding the creation of an Office of Patient Affairs that would help coordinate patient involvement at FDA.

Expanded access inovolves accessing unapproved therapies outside of clinical trials.  This process has been in existience since the late 1980s, and currently there have been calls to change the process.